Related Experiment Video

Updated: May 11, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective

Soosung Kang1, Garry Cooper, Sara Fernandez Dunne

  • 1Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, and Center for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, Illinois 60208, USA.

Journal of Medicinal Chemistry
|May 9, 2013
PubMed

Insights

Researchers explored pyrimidinetriones (PYTs) as potential drugs for Parkinson's disease by studying their interaction with CaV1.3 calcium channels. This work enhances understanding of PYTs for developing new treatments targeting these channels.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • CaV1.3 L-type calcium channels (LTCCs) are implicated in Parkinson's disease pathogenesis due to their role in dopaminergic neuron death.
  • Selective inhibition of CaV1.3 LTCCs is crucial for therapeutic efficacy and minimizing side effects, distinguishing it from other isoforms like CaV1.2.

Purpose of the Study:

  • To investigate the structure-activity relationship (SAR) of pyrimidinetriones (PYTs) targeting CaV1.3 and CaV1.2 LTCCs.
  • To characterize the binding sites of PYTs on CaV1.3 and CaV1.2 LTCCs.
  • To identify key structural features of PYTs for optimizing CaV1.3 selectivity and binding affinity.

Main Methods:

  • Systematic modification of substituents on the cyclopentyl and arylalkyl groups of the PYT scaffold.
  • Structure-activity relationship (SAR) studies to assess binding affinity and selectivity for CaV1.3 and CaV1.2 LTCCs.
  • Lead optimization and diversification of PYT compounds.

Main Results:

  • Detailed SAR characterization of PYTs against CaV1.3 and CaV1.2 LTCCs.
  • Identification of specific binding site interactions for PYTs on both LTCC isoforms.
  • Discovery of four critical moieties influencing PYT selectivity and binding affinity for CaV1.3.

Conclusions:

  • The study significantly advances the SAR understanding of PYTs for CaV1.3 and CaV1.2 LTCCs.
  • Identified PYT structural modifications enhance lead optimization for potential Parkinson's disease therapeutics.
  • Highlights the potential of PYTs as a versatile scaffold for developing selective CaV1.3 inhibitors.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...